NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November: November 4-6: BIO-Europe. Members of Immunic's management, business development and investor relations teams will participate in partnering activities at this conference in Stockholm ...

Group 1 - The company specializes in medium and small-cap markets while also providing updates on blue-chip companies, commodities, and broader investment stories [2] - Proactive delivers news and unique insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [2] - The company has a strong focus on technology adoption, utilizing automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [2] Group 2 - Proactive's news team operates from key finance and investing hubs globally, including London, New York, Toronto, Vancouver, Sydney, and Perth [1] - The company aims to provide fast, accessible, informative, and actionable business and finance news content to a global investment audience [1] - Proactive's content is produced independently by experienced and qualified teams of news journalists [1]

Core Insights - The Independent Data Monitoring Committee (IDMC) confirmed that the predetermined futility criteria for the phase 3 ENSURE program have not been met, allowing the trials to continue as planned [1][2] - The ENSURE program is expected to be completed in 2026, with the trials evaluating the efficacy of vidofludimus calcium for treating relapsing multiple sclerosis (RMS) [1][3] Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, with its lead asset being vidofludimus calcium (IMU-838) [5][6] - Vidofludimus calcium is designed as a next-generation treatment option for multiple sclerosis and has shown a favorable pharmacokinetic, safety, and tolerability profile in over 1,800 individuals [5][6] Clinical Trial Details - The ENSURE program consists of two identical multicenter, randomized, double-blind phase 3 trials (ENSURE-1 and ENSURE-2), each enrolling approximately 1,050 adult patients with active RMS across more than 100 sites in over 15 countries [3] - The primary endpoint for both trials is the time to first relapse, assessed over a period of up to 72 weeks, with key secondary endpoints including disability progression and changes in brain volume [3] Future Milestones - The next clinical milestone for vidofludimus calcium is the topline readout of the phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS), expected to be released in April of the following year [2]

Company Overview - Proactive is a financial news and online broadcast company that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The company has a presence in key finance and investing hubs, with bureaus and studios located in London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance workflows and content production, utilizing automation and software tools, including generative AI [4] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [4]

– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All Progressive Multiple Sclerosis Subtypes – – Clinical Signal Shown for Vidofludimus Calcium on Post COVID Fatigue May Be Related to Epstein-Barr Virus Reactivation; Preventing This Reactivation May Contribute to Fatigue Reduction in Multiple Sclerosis Patients – – Preclinical Data Showed Improved Neuronal ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Core Insights - Immunic, Inc. is hosting a Multiple Sclerosis (MS) Research and Development Day on September 10, 2024, to discuss its lead asset, vidofludimus calcium (IMU-838), which is being developed for relapsing and progressive MS patients [1] - The company will participate in several scientific and investor conferences in September, including the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 18-20, where data on vidofludimus calcium will be presented [1][2] - Vidofludimus calcium is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive MS, showing therapeutic activity in previous trials [6] Company Events - The MS R&D Day will feature Immunic's management and renowned experts discussing the MS landscape and the potential of vidofludimus calcium [1] - The company will present data on vidofludimus calcium in an oral presentation and three ePosters at the ECTRIMS conference [1][2] - Additional presentations will occur at the DMDG 50th Open Meeting and the 20th International Celiac Disease Symposium, showcasing data from various clinical trials [4][5] Product Development - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and anti-inflammatory properties [6] - IMU-856, another product targeting Sirtuin 6 (SIRT6), is in preparations for a phase 2 clinical trial aimed at treating celiac disease [6] - The company is also developing IMU-381, a next-generation molecule for gastrointestinal diseases, currently in preclinical testing [6]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

– Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the second quarter ended June 30, 2024, including a corporate update, on Thursday, August 8, 2024, before the opening of the U.S. financial markets. A webcast wil ...